Enasidenib, an oral targeted inhibitor of the isocitrate dehydrogenase-2 (IDH2) enzyme, was approved for the treatment of adult patients with R/R AML with an IDH-2 mutation as detected by an FDA-approved test [12]. The gene discussed is IDH2; the disease is acute myeloid leukemia.